Included in the formulation
АТХ:D.06.B.B.06 Penciclovir
Pharmacodynamics:Capture and phosphorylation penciclovir using viral thymidine kinase (affinity to viral enzyme 200 times higher than the affinity for host cells thymidine) - pentsiklovirmonofosfata formation, selective accumulation in virus-infected cells. Conversion of the latter (under the influence cell phosphorylases) in pentsiklovirtrifosfat: competitive inhibition of viral DNA polymerase (and to a minor extent the DNA polymerase of the host cells); incorporation into the viral DNA - replication stop (no hydroxy group at the 3'-position of the ribose ring), binding defective DNA viral DNA polymerase and its inhibition irreversible. 100 times weaker inhibits viral DNA polymerase in comparison with acyclovir has a higher intracellular concentration and longer half-life.
Pharmacokinetics:The connection with plasma proteins is less than 20%. Undergoes biotransformation in the liver (5%). The half-life is 2 hours, inside the cell in the form of penciclovirtriphosphate - 7-20 hours. Elimination in unchanged form by the kidneys (90%) and with feces (10%).
Indications:Recurrent simple herpes with localization on the lips and face.
I.B00-B09.B00 Infections caused by the herpes simplex virus [herpes simplex]
Contraindications:Hypersensitivity, children under 12 years.
Carefully:Pregnancy, breast-feeding.
Pregnancy and lactation:Use during pregnancy is possible by strict indications in cases where the expected benefit to the mother exceeds the potential risk to the fetus. The action category for fetus by FDA is B.
If you need to use during breastfeeding, you need to consult a doctor.
Dosing and Administration:The drug is applied to the rash every 2 hours during the day for 4 days.
Side effects:Burning, paresthesia, numbness in the place of application. Headache, hypoesthesia, taste disorder, rash, redness.
Overdose:When an overdose occurs headache, convulsions, drowsiness, coma, acute renal failure. Treatment is symptomatic.
Interaction:Zidovudine - the appearance of fatigue. Interferon-alpha is a risk of developing kidney failure.
Mycophenolic acid - mutual suppression of elimination (especially in the background of chronic renal failure).
Nephrotoxic agents increase the likelihood of developing renal failure.
Probenecid - an increase in the toxic effect of penciclovir.
Special instructions:The drug should not be applied to mucous membranes or to the skin in the eye area. Avoid contact with eyes.